CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (ustekinumab). Ustekinumab is used for treating Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
